In 2014, a new emerging human influenza (affecting males) occurred in China. This has finally been approved to be H5N6 influenza infection. This is believed to be a result of the new reassortment of the virus. ,, After that, there were two additional human cases (both males) of H5N6 influenza infections. Of interest is this new infection that has a high severity. Without atypical nonrespiratory clinical features, this infection rapidly developed into lower respiratory tract infection, resulting in pneumonia. The mortality rate of the infection is 66.7%, which is considerably high compared to other new emerging influenzas. Similar to the other new emerging cross-species avian influenzas, contact with poultry is considered to be a risk. Of interest is this infection, which is very severe with a high death rate. Nevertheless, the disease seems to be successfully confined to China without any new case outside China.
Qi X, Cui L, Yu H, Ge Y, Tang F. Whole-genome sequence of a reassortant H5N6 avian influenza virus isolated from a live poultry market in China, 2013. Genome Announc 2014;11:2. pii: e00706-14.
Bi Y, Mei K, Shi W, Liu D, Yu X, Gao Z, et al. Two novel reassortants of avian influenza A(H5N6) virus in China. J Gen Virol 2015. pii: vir.0.000056.
Wu H, Lu R, Peng X, Xu L, Cheng L, Lu X, et al. Novel reassortant highly pathogenic H5N6 avian influenza viruses in poultry in China. Infect Genet Evol 2015;31:64-7.